Modeling hematopoietic conditions has been a really important advance for our understanding and design of new therapies. And I would say clonal hematopoiesis, being a relatively new phenomenon that we’ve observed, can be modeled in many ways. Of course, we can do conventional genetically engineered mouse models, but I think one of the most exciting things is that with the advent of CRISPR-Cas9 genome editing and now more advanced and alternative methods of genome editing that we can really make high-fidelity models of clonal hematopoiesis directly in human hematopoietic stem and progenitor cells...
Modeling hematopoietic conditions has been a really important advance for our understanding and design of new therapies. And I would say clonal hematopoiesis, being a relatively new phenomenon that we’ve observed, can be modeled in many ways. Of course, we can do conventional genetically engineered mouse models, but I think one of the most exciting things is that with the advent of CRISPR-Cas9 genome editing and now more advanced and alternative methods of genome editing that we can really make high-fidelity models of clonal hematopoiesis directly in human hematopoietic stem and progenitor cells. And this is really important because large-scale genome studies are showing that clonal hematopoiesis effects can vary across the diverse human population. So while the mouse models are super important and have taught us a lot about the individual genes and their mutations, the next phase of research really will require us to delve deeply into human cells along with human variation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
